| Zhang, Yongchang |
NCT05055908: Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors |
|
|
| Recruiting | 3 | 12000 | RoW | Pemetrexed plus Pembrolizumab, Bevacizumab, Pembrolizumab, Pemetrexed | Hunan Province Tumor Hospital | Lung Cancer | 07/25 | 09/27 | | |
NCT05549037: Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC |
|
|
| Recruiting | 3 | 210 | RoW | Pembrolizumab, Sintilimab, time-of-day of administration of immunochemotherapy | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 12/24 | 12/25 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 2/3 | 1200 | RoW | Anlotinib plus the same Immune Checkpoint Inhibitors., Pembrolizumab, Sintilimab etc. have been used in the previous treatment., Anlotinib plus the new Immune Checkpoint Inhibitors., Pembrolizumab, Sintilimab etc. have not been used in the previous treatment., Anlotinib, Anlotinib monotherapy. | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 03/28 | 03/29 | | |
NCT05014464: ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 90 | RoW | Crizotinib, Alectinib, Brigatinib, Lorlatinib, Pemetrexed, immune checkpoint inhibitors, Carboplatin, Paclitaxel | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 06/26 | 08/27 | | |
ESSENTIAL, NCT05284539: Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer |
|
|
| Recruiting | 2 | 760 | RoW | Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab, Pemetrexed, Bevacizumab, Pembrolizumab, Atezolizumab | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 09/26 | 10/27 | | |
NCT04951947: JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer |
|
|
| Recruiting | 2 | 30 | RoW | JS201 combine with Lenvatinib | Hunan Province Tumor Hospital | Small-cell Lung Cancer | 12/24 | 06/25 | | |
TOGATHER, NCT04144608: Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC |
|
|
| Completed | 2 | 40 | RoW | Toripalimab, platinum-based chemotherapy | Yongchang Zhang | Advanced Non Small Cell Lung Cancer | 06/22 | 07/23 | | |
PIKACHU, NCT04322890: Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation |
|
|
| Recruiting | 2 | 6000 | RoW | Osimertinib, Erlotinib, Gefitinib, Furmonertinib, Almonertinib etc., Alectinib 150 MG, Lorlatinib, Alectinib, Brigatinib, Ceritinib etc., Crizotinib 250 MG, Entrectinib, Savolitinib, Crizotinib., Crizotinib, Chemotherapy, Pemetrexed, Cisplatin, Pralsetinib etc. | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROS1 Gene Mutation, MET Gene Mutation | 12/26 | 12/27 | | |
| Recruiting | 2 | 43 | RoW | Anlotinib and Docetaxel | Yongchang Zhang | Non-Squamous Non Small Cell Lung Cancer | 12/24 | 06/25 | | |
NCT04322578: Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC |
|
|
| Recruiting | 2 | 120 | RoW | Crizotinib, Savolitinib, Pemetrexed, immune checkpoint inhibitors, Carboplatin, Bevacizumab | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 03/25 | 03/26 | | |
NCT05584267: Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy |
|
|
| Recruiting | 2 | 140 | RoW | radiotherapy, Chemotherapy + immunotherapy | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 11/25 | 12/26 | | |
NCT05266846: Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK |
|
|
| Recruiting | 2 | 78 | RoW | Pembrolizumab injection, pemetrexed, Bevacizumab, CISPLATIN | Hunan Province Tumor Hospital | ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy | 11/26 | 02/27 | | |
| Recruiting | 2 | 71 | RoW | SHR-1701 Combined With Fluazopalil | Hunan Province Tumor Hospital | Non-Small Cell Lung Cancer | 12/24 | 06/25 | | |
NCT04144569: PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC |
|
|
| Recruiting | 2 | 30 | RoW | PD-1 Combined With Pyrotinib | Yongchang Zhang | HER2 Insertion Mutation Positive Advanced NSCLC | 12/24 | 12/24 | | |
EPIC, NCT06440954: Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases |
|
|
| Recruiting | 2 | 220 | RoW | Intrathecal pemetrexed, pemetrexed | Hunan Province Tumor Hospital, Hunan Cancer Hospital | Non-Small Cell Lung Cancer | 12/26 | 04/27 | | |
NCT05295212: Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB |
|
|
| Recruiting | 2 | 120 | RoW | Atezolizumab | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 12/24 | 07/25 | | |
WUKONG-32, NCT06348927: Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC |
|
|
| Recruiting | 2 | 52 | RoW | sunvozertinib in combination with Anlotinib | Hunan Province Tumor Hospital | Non-Small Cell Lung Cancer | 10/25 | 04/27 | | |
| Recruiting | 2 | 100 | RoW | sunvozertinib in combination with Anlotinib | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 12/25 | 12/27 | | |
FORCE, NCT05379803: High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases |
|
|
| Recruiting | 2 | 40 | RoW | Furmonertinib, AST2818 | Hunan Province Tumor Hospital | Non-Small Cell Lung Cancer | 12/24 | 03/25 | | |
Example, NCT06604351: Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction |
|
|
| Not yet recruiting | 2 | 39 | RoW | Sintilimab, Nab-Paclitaxel, and Carboplatin | Hunan Province Tumor Hospital | Non-Small Cell Lung Cancer | 10/27 | 05/29 | | |
NCT06537297: Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases |
|
|
| Not yet recruiting | 2 | 30 | RoW | Intrathecal Pemetrexed and high-dose Furmonertinib plus bevacizumab, intrathecal pemetrexed, high-dose furmonertinib, bevacizumab | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 08/25 | 04/26 | | |
NCT05296603: Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 83 | RoW | IBI-322 Plus Lenvatinib | Hunan Province Tumor Hospital | Small Cell Lung Cancer | 10/24 | 12/25 | | |
NCT06634667: Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance |
|
|
| Not yet recruiting | 2 | 30 | RoW | third-generation EGFR-TKI combined with anlotinib | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 08/26 | 04/27 | | |
NCT05296278: Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC |
|
|
| Recruiting | 2 | 70 | RoW | IBI-323 combined with bevacizumab plus Platinum | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 12/25 | 04/26 | | |
NCT06706219: Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Patients With Initially Unresectable Stage III NSCLC |
|
|
| Not yet recruiting | 2 | 50 | RoW | Sacituzumab tirumotecan plus pembrolizumab | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer (Stage III) | 03/28 | 05/29 | | |
NCT06057571: Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor |
|
|
| Recruiting | 2 | 50 | RoW | TT-00420 (tinengotinib) | TransThera Sciences (Nanjing), Inc. | Cholangiocarcinoma Metastatic | 06/25 | 10/25 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
Helpful, NCT06521034: First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer |
|
|
| Completed | 1/2 | 124 | RoW | FHND-9041, EGFR-TKI | Yongchang Zhang, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Sensitizing Mutation | 05/21 | 05/21 | | |
NCT06220318: Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 155 | RoW | C019199, C019199 Tablets, Sintilimab, IBI308 | Fujian Haixi Pharmaceuticals Co., Ltd. | Solid Tumor | 08/26 | 08/26 | | |
NCT06306456: A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC |
|
|
| Recruiting | 1/2 | 94 | RoW | GH21, Tagrisso | Suzhou Genhouse Bio Co., Ltd. | Non-Small Cell Lung Cancer With EGFR Mutation | 12/25 | 12/26 | | |
NCT06109558: The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC |
|
|
| Recruiting | 1/2 | 120 | RoW | LMV-12(HE003), Osimertinib | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer, RET Gene Mutation, MET Amplification, EGF-R Positive Non-Small Cell Lung Cancer | 12/26 | 07/27 | | |
| Recruiting | 1/2 | 430 | RoW | IBI363, IBI325, Lenvatinib | Hunan Province Tumor Hospital, Xiangya Hospital of Central South University | Advanced Solid Tumor | 12/26 | 09/28 | | |
NCT04777084: The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC. |
|
|
| Recruiting | 1 | 120 | RoW | IBI318 | Hunan Province Tumor Hospital | Non-Small Cell Lung Cancer | 12/24 | 12/25 | | |
NCT06166472: A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor |
|
|
| Not yet recruiting | 1 | 72 | RoW | AK132 | Akeso | Advanced Malignant Solid Tumor | 04/26 | 07/26 | | |
| Recruiting | 1 | 117 | RoW | SG2918 | Hangzhou Sumgen Biotech Co., Ltd. | Advanced Malignant Tumors | 12/25 | 12/26 | | |
| Recruiting | 1 | 150 | RoW | TQB2922 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Advanced Cancer | 12/24 | 12/25 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
| Recruiting | 1 | 556 | RoW | IBI363 + chemotherapy, IBI363 + Investigator's Choice SOC | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Malignancies | 06/25 | 12/26 | | |
NCT06536400: Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation |
|
|
| Recruiting | 1 | 316 | RoW | HSK42360 | Haisco Pharmaceutical Group Co., Ltd. | Solid Tumors | 08/26 | 07/27 | | |
| Recruiting | 1 | 122 | RoW | SG1827 | Hangzhou Sumgen Biotech Co., Ltd. | Advanced Solid Tumors | 12/24 | 03/25 | | |
| Recruiting | 1 | 71 | RoW | TQB2103 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Advanced Malignant Neoplasm | 05/25 | 05/25 | | |
NCT06174857: Efficacy of Osimertinib in Patients With Lung Cancer |
|
|
| Recruiting | N/A | 100 | RoW | | Hunan Province Tumor Hospital | Advanced Non-Small Cell Lung Cancer | 06/25 | 09/25 | | |
NCT05059951: Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer |
|
|
| Recruiting | N/A | 15000 | RoW | Immune checkpoint inhibitor, Chemotherapy | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 09/26 | 03/28 | | |
OMESIA, NCT05129202: Outcomes With Immune Checkpoint Inhibitor for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases |
|
|
| Completed | N/A | 200 | RoW | immune therapy | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 09/21 | 10/22 | | |
POSEIDON, NCT04322591: Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the Trial |
|
|
| Recruiting | N/A | 70 | RoW | | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 12/24 | 03/25 | | |
NCT04324164: Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC |
|
|
| Recruiting | N/A | 800 | RoW | Third-generation EGFR-TKI, EGFR-TKI | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 12/25 | 12/27 | | |
NCT03647111: Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 120 | RoW | Crizotinib | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 12/24 | 12/25 | | |
NCT03646994: Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 40 | RoW | Crizotinib | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 12/24 | 12/25 | | |
NCT03647098: Analysis of Survival Status of KRAS Mutation Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 1500 | RoW | Chemotherapy., pemetrexed | Hunan Province Tumor Hospital | KRAS G12C, Non-small Cell Lung Cancer, KRAS G12D, KRAS G12V, KRAS G12R, KRAS G12Y, KRAS G13N | 12/26 | 12/28 | | |
NCT04777175: A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 186 | RoW | immunity therapy | Yongchang Zhang, Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 01/25 | 01/25 | | |
PERSPECT, NCT04324151: Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC |
|
|
| Recruiting | N/A | 70 | RoW | | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 12/24 | 03/25 | | |
NCT04324125: Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC |
|
|
| Recruiting | N/A | 70 | RoW | | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 12/24 | 03/25 | | |
NCT05450081: Association Between the Results of Specific Genetic Tests and the Efficacy of Targeted Therapies in Patients |
|
|
| Completed | N/A | 140 | RoW | | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 03/23 | 10/23 | | |
NCT06073938: Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement |
|
|
| Recruiting | N/A | 30 | RoW | NHWD-870 | Hunan Province Tumor Hospital | Advanced Solid Tumors or Lymphomas | 12/24 | 06/25 | | |
| Active, not recruiting | N/A | 150 | RoW | PD-1 inhibitor based immunotherapy | Shanghai Pulmonary Hospital, Shanghai, China | Non-small Cell Lung Cancer | 01/24 | 01/25 | | |
NCT05991180: Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung Cancer |
|
|
| Recruiting | N/A | 160 | RoW | | Hunan Province Tumor Hospital | Extensive-stage Small-cell Lung Cancer | 12/24 | 12/25 | | |
| Recruiting | N/A | 130 | RoW | No treatment is included in this study | Hunan Province Tumor Hospital | Advanced Lung Squamous Cell Carcinoma | 12/24 | 12/25 | | |
NCT05991193: A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 100 | RoW | | Hunan Province Tumor Hospital | NSCLC | 08/25 | 12/25 | | |
NCT05991206: A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC |
|
|
| Recruiting | N/A | 200 | RoW | | Hunan Province Tumor Hospital | NSCLC | 12/25 | 08/26 | | |
| Gu, Shanzhi |
NCT03236649: The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects |
|
|
| Terminated | 3 | 89 | RoW | Icaritin, Sorafenib Tosylate Tablets | Beijing Shenogen Biomedical Co., Ltd, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Eastern Theater General Hospital,QinHuai District Medical Area, Peking University Cancer Hospital & Institute, Chinese PLA General Hospital, Beijing Hospital, General Hospital of Chinese Armed Police Forces, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Cancer Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Tianjin Medical University Cancer Institute and Hospital, The Fourth Hospital of Hebei Medical University, Hunan Cancer Hospital, The First Hospital of Jilin University, 307 Hospital of PLA, Fudan University, Henan Cancer Hospital, Jilin Provincial Tumor Hospital, First Affiliated Hospital of Harbin Medical University, First Affiliated Hospital Bengbu Medical College, The First Affiliated Hospital of Soochow University, Tongji Hospital, Beijing YouAn Hospital | Hepatocellular Carcinoma (HCC) | 02/22 | 02/22 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
ALTN-AK105-III-02, NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Active, not recruiting | 3 | 648 | RoW | AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma (HCC) | 12/26 | 12/26 | | |
AK104-308, NCT06371157: A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 3 | 469 | RoW | AK104, Lenvatinib, TACE, Placebo for AK104, Placebo for Lenvatinib | Akeso | Hepatocellular Carcinoma | 10/25 | 05/26 | | |
NCT04329429: A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer |
|
|
| Active, not recruiting | 2 | 57 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection | RemeGen Co., Ltd. | Biliary Tract Cancer | 11/23 | 06/24 | | |
NCT04000737: YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) |
|
|
| Recruiting | 2 | 125 | US, RoW | YIV-906+Sorafenib, Placebo+Sorafenib | Yiviva Inc. | Advanced Hepatocellular Carcinoma | 12/23 | 05/24 | | |
AK104-IIT-C-M-0035, NCT06406634: Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Cadonilimab, AK104, Lenvatinib | Hunan Cancer Hospital | Hepatocellular Carcinoma | 04/26 | 04/27 | | |
NCT04838964: A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer |
|
|
| Recruiting | 2 | 80 | RoW | MRG003 | Shanghai Miracogen Inc. | Advanced or Metastatic Biliary Tract Cancer | 10/24 | 11/24 | | |
NCT06057571: Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor |
|
|
| Recruiting | 2 | 50 | RoW | TT-00420 (tinengotinib) | TransThera Sciences (Nanjing), Inc. | Cholangiocarcinoma Metastatic | 06/25 | 10/25 | | |
NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 70 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Intrahepatic Cholangiocarcinoma (ICC) | 05/26 | 12/26 | | |
| Recruiting | 1/2 | 222 | RoW | SHR-1701, Famitinib | Jiangsu HengRui Medicine Co., Ltd. | Solid Tumor | 12/22 | 10/23 | | |
NCT05176665: EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers |
|
|
| Recruiting | 1/2 | 152 | US, RoW | EMB-01, FIT-013a | Shanghai EpimAb Biotherapeutics Co., Ltd., Labcorp Corporation of America Holdings, Inc | Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor | 12/25 | 12/25 | | |
NCT05652920: Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC |
|
|
| Recruiting | 1/2 | 105 | RoW | Ori-C101 | OriCell Therapeutics Co., Ltd. | Hepatocellular Carcinoma | 12/26 | 12/26 | | |
NCT04825392: A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | HX008 | Taizhou Hanzhong biomedical co. LTD | Advanced Solid Tumor | 05/21 | 12/21 | | |
NCT04605185: Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma |
|
|
| Active, not recruiting | 1 | 18 | RoW | Donafenib Tosilate Tablets, Toripalimab Injection, JS001 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Unresectable Hepatocellular Carcinoma | 12/24 | 12/24 | | |
| Recruiting | 1 | 96 | US, RoW | GQ1001 | GeneQuantum Healthcare (Suzhou) Co., Ltd., Conjugate Light (Australia) Pty Ltd | HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor | 03/24 | 05/24 | | |
| Recruiting | 1 | 34 | RoW | TQB2223 injection, Penpulimab Injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma | 02/25 | 10/25 | | |
| Recruiting | 1 | 122 | RoW | SG1827 | Hangzhou Sumgen Biotech Co., Ltd. | Advanced Solid Tumors | 12/24 | 03/25 | | |
| Li, Yajun |
NCT06521255: Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Recruiting | 3 | 244 | RoW | Tafasitamab, Lenalidomide, Gemcitabine, Oxaliplatin, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | DLBCL | 09/28 | 12/29 | | |
NCT06082102: Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Compared to Placebo Plus R2 in r/r Marginal Zone Lymphoma |
|
|
| Recruiting | 3 | 324 | RoW | Orelabrutinib, Lenalidomide, Rituximab, Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Relapsed/Refractory Marginal Zone Lymphoma | 08/27 | 02/30 | | |
NCT06601504: Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL |
|
|
| Recruiting | 2 | 60 | RoW | HMPL-760 planned dose 1, R-GemOx, Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection, HMPL-760 placebo planned dose 1, HMPL-760 planned dose 2, HMPL-760 placebo planned dose 2 | Hutchmed | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 05/26 | 11/26 | | |
TQB3702-II-02, NCT06566586: A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma |
|
|
| Recruiting | 2 | 80 | RoW | TQB3702 tablets+Chemotherapy regimen | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | B-cell Lymphoma | 03/26 | 12/27 | | |
NCT05269940: A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies |
|
|
| Completed | 1/2 | 40 | RoW | ZX-101A | Nanjing Zenshine Pharmaceuticals | Non Hodgkin Lymphoma, Peripheral T Cell Lymphoma, CLL/SLL | 01/23 | 07/24 | | |
TQB3909-Ib/II-02, NCT05959694: A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . |
|
|
| Recruiting | 1/2 | 107 | RoW | TQB3909 tablet | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/25 | 06/26 | | |
| Recruiting | 1 | 105 | RoW | ICP-248 | Beijing InnoCare Pharma Tech Co., Ltd. | Hematological Malignancies | 08/24 | 10/26 | | |
| Recruiting | 1 | 92 | RoW | TQB2223 injection+ Penpulimab Injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Cancer | 01/25 | 01/26 | | |
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL |
|
|
| Recruiting | N/A | 200 | RoW | Relmacabtagene Autoleucel, JWCAR029 | Shanghai Ming Ju Biotechnology Co., Ltd. | Large B-cell Lymphoma | 12/24 | 12/24 | | |
